Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved paclitaxel (80) in combination with trastuzumab therapy - 7 day (12 weeks) for reimbursement as a treatment option for the adjuvant treatment of HER2 positive, node-negative breast cancer of tumor size <= 3 cm.
This is written in the approval document as:
Adjuvant Treatment of HER2 positive, Node-Negative Breast Cancer of tumour size <= 3cm.
Citation
PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks), 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Paclitaxel, Trastuzumab |